BTIG analyst Ryan Zimmerman lowered the firm’s price target on Staar Surgical to $67 from $80 and keeps a Buy rating on the shares. The company’s announced CEO change was "abrupt" and with little clarity on why it happened, the analyst tells investors in a research note. Zimmerman adds that if new CEO Tom Frinzi had been involved in Staar’s 3-year strategic plan as indicated, he would have been comfortable with reiterating the company FY23 guidance, which the management omitted. The analyst further notes that the next step is likely a reset of FY23 guidance.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STAA:
- Staar Surgical CEO Caren Mason to retire, Thomas Frinzi to succeed
- Staar Surgical initiated with a Hold at Stifel
- Needham healthcare analyst to hold an analyst/industry conference call
- Staar Surgical price target lowered to $79 from $88 at Canaccord
- Staar Surgical upgraded to Buy from Neutral at Sidoti